[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560974":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":32,"responsibleParty":53,"collaborators":56,"id":58,"slug":20,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University of Cambridge","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study cohort","EXPERIMENTAL","All patient's enrolled in the study will undergo an 18F-FET-PET",[13],"Diagnostic Test: 18F-Fluoro-ethyl-tyrosine (FET) PET",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","18F-Fluoro-ethyl-tyrosine (FET) PET","18F-Fluoro-ethyl-tyrosine PET study of the pituitary",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Mark Gurnell, MD, PhD","Cambridge University Hospitals NHS Foundation Trust","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"James MacFarlane","CONTACT","01223 250882","jm2267@medschl.cam.ac.uk",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Cambridge University Hospitals","RECRUITING","Cambridge","Cambridgeshire","CB2 0QQ","United Kingdom","UK",{"type":42,"coordinates":43},"Point",[44,45],0.11667,52.2,{"lat":45,"lon":44},[48,52],{"name":49,"role":29,"phone":50,"phoneExt":20,"email":51},"Mark Gurnell, PhD FRCP","+44-1223-245151","mark.gurnell2@nhs.net",{"name":49,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":25,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Professor Mark Gurnell","Professor of Clinical Endocrinology",[57],{"name":24,"class":6},"100560974",false,"NCT06584123","Molecular Pituitary Imaging Using 18F-FET PET","Exploring the Potential for 18F-fluoro-ethyl-tyrosine (18F-FET) to Enable Wider Access to Molecular Imaging for Patients With Pituitary Adenomas (FET-pit-PET Study)","FET-pit-PET","Inclusion criteria\n\n* Participant is willing and able to give informed consent for participation in the study\n* Male or female, age 18 or above\n* Presence of pituitary adenoma suspected on the basis of clinical\u002Fbiochemical and\u002For radiological findings\n* Previous 11C-Met-PET\u002FCT\n\nExclusion criteria\n\n* Inability to give informed consent\n* Pregnancy or suspected pregnancy\n* Inability to lie supine for 30-60 minutes\n* Patient body habitus above scanner dimensions\n* Known allergy to intravenous radiographic contrast agents","ALL","18 Years","100 Years",{"count":69,"type":70},20,"ESTIMATED","INTERVENTIONAL",[73],"NA","The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.",[76],"Pituitary Adenoma",[78,79,80],"Molecular pituitary imaging","Functional pituitary imaging","18F-FET PET","2026-01-05",{"date":83,"type":84},"2026-01-06","ACTUAL",{"date":86,"type":84},"2024-09-03",{"date":88,"type":70},"2026-12-31",{"name":5,"class":6},1]